OOIR: Observatory of International Research

Papers

(The H4-Index of Clinical Immunology is 31. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-10-01 to 2024-10-01.)

Article	Citations
Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy	191
COVID-19: A review of therapeutic strategies and vaccine candidates	175
Do COVID-19 RNA-based vaccines put at risk of immune-mediated diseases? In reply to “potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in aut	164
The efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives	148
Interrelations between COVID-19 and other disorders	119
Recent advances on signaling pathways and their inhibitors in rheumatoid arthritis	115
Therapeutic blockade of inflammation in severe COVID-19 infection with intravenous N-acetylcysteine	109
Influenza infection, SARS, MERS and COVID-19: Cytokine storm – The common denominator and the lessons to be learned	106
Anti-complement C5 therapy with eculizumab in three cases of critical COVID-19	101
SARS-CoV-2 infections in children and young people	85
Neurologic adverse events among 704,003 first-dose recipients of the BNT162b2 mRNA COVID-19 vaccine in Mexico: A nationwide descriptive study	85
Possible role of HLA class-I genotype in SARS-CoV-2 infection and progression: A pilot study in a cohort of Covid-19 Spanish patients	82
Micronutrients as immunomodulatory tools for COVID-19 management	80
Characterization of PANoptosis patterns predicts survival and immunotherapy response in gastric cancer	73
Galectin-3 regulates microglial activation and promotes inflammation through TLR4/MyD88/NF-kB in experimental autoimmune uveitis	61
Guillain-Barré syndrome is infrequent among recipients of the BNT162b2 mRNA COVID-19 vaccine	59
Laboratory biomarkers associated with COVID-19 severity and management	59
Covid-19 vaccine and autoimmunity: Awakening the sleeping dragon	47
Genetic justification of severe COVID-19 using a rigorous algorithm	47
Macrophages in tumor: An inflammatory perspective	46
Activation of classical and alternative complement pathways in the pathogenesis of lung injury in COVID-19	43
Major reduction of NKT cells in patients with severe COVID-19 pneumonia	43
Identification of critical ferroptosis regulators in lung adenocarcinoma that RRM2 facilitates tumor immune infiltration by inhibiting ferroptotic death	42
Natural killer cells play an important role in virus infection control: Antiviral mechanism, subset expansion and clinical application	41
The microbiota-mediated dietary and nutritional interventions for COVID-19	35

Interferon gamma, TGF-β1 and RANTES expression in upper airway samples from SARS-CoV-2 infected patients	34
Gut dysbiosis and multiple sclerosis	33
On the genetics and immunopathogenesis of COVID-19	32
The resurgence of a neglected orthopoxvirus: Immunologic and clinical aspects of monkeypox virus infections over the past six decades	31
Kidney tubular epithelial cell ferroptosis links glomerular injury to tubulointerstitial pathology in lupus nephritis	31
Systemic lupus erythematosus as a genetic disease	31
Treatment of B-cell depleted COVID-19 patients with convalescent plasma and plasma-based products	31